Literature DB >> 10064076

A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion.

E Zorn1, T Hercend.   

Abstract

In recent years, experiments based on the in vitro stimulation of either autologous peripheral blood lymphocytes or tumor-infiltrating lymphocytes with melanoma cells have shown that distinct members of the large MAGE gene family encode tumor-associated antigenic peptides. However, little is still known about natural anti-MAGE responses in vivo. We have studied a case of spontaneously regressing human melanoma, hypothesizing that in this unique situation, the host immune system had developed an efficient cytotoxic T lymphocyte (CTL) response against the cancer cells. Amongst the dense tumor infiltrate, certain clonal populations of T cells were shown to be amplified, thereby suggesting that an antigen-driven selection had occurred at the tumor site. One of the expanded tumor-infiltrating lymphocytes was shown to be a Vbeta13+ CD8+ CTL displaying a strong and selective cytotoxic activity against the autologous melanoma cells. Here we show that this cytotoxic T cell clone recognizes a MAGE-6-encoded peptide. MAGE-6 is therefore the fourth gene of the MAGE family shown to encode antigenic peptide recognized by T cells. Together, these data provide further evidence that T cell responses against MAGE antigens may naturally develop in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064076     DOI: 10.1002/(SICI)1521-4141(199902)29:02<602::AID-IMMU602>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

2.  Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.

Authors:  Jan C Schmollinger; Robert H Vonderheide; Kara M Hoar; Britta Maecker; Joachim L Schultze; F Stephen Hodi; Robert J Soiffer; Ken Jung; Marcelo J Kuroda; Norman L Letvin; Edward A Greenfield; Martin Mihm; Jeffery L Kutok; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

3.  Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.

Authors:  Jianping Huang; Hung T Khong; Mark E Dudley; Mona El-Gamil; Yong F Li; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2005 May-Jun       Impact factor: 4.456

4.  ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.

Authors:  F Stephen Hodi; Jan C Schmollinger; Robert J Soiffer; Ravi Salgia; Thomas Lynch; Jerome Ritz; Edwin P Alyea; Jihong Yang; Donna Neuberg; Martin Mihm; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

Review 5.  Immune targets and neoantigens for cancer immunotherapy and precision medicine.

Authors:  Rong-Fu Wang; Helen Y Wang
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

Review 6.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 7.  How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.

Authors:  Jonathan L Messerschmidt; George C Prendergast; Gerald L Messerschmidt
Journal:  Oncologist       Date:  2016-02-01

8.  Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Authors:  Leeann T Blalock; Jennifer Landsberg; Michelle Messmer; Jian Shi; Angela D Pardee; Ronald Haskell; Lazar Vujanovic; John M Kirkwood; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

9.  Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.

Authors:  Grégoire Wieërs; Nathalie Demotte; Danièle Godelaine; Pierre Van der Bruggen
Journal:  Cancers (Basel)       Date:  2011-07-18       Impact factor: 6.639

10.  The signature of liver cancer in immune cells DNA methylation.

Authors:  Yonghong Zhang; Sophie Petropoulos; Jinhua Liu; David Cheishvili; Rudy Zhou; Sergiy Dymov; Kang Li; Ning Li; Moshe Szyf
Journal:  Clin Epigenetics       Date:  2018-01-18       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.